Last Price$4.3(4.0%)
Market Cap$211.4B
(42.1%)
Industry median - 13.1%
5Y Historical average - 327.1%
23.4%
Industry median - 0.6%
5Y Historical average - 20.3%
(39.1%)
Industry median - (20.7%)
5Y Historical average - 6.3%
6.6%
Industry median - (1.5%)
5Y Historical average - 146.1%
SLN Growth Rating
SLN Growth rating
6.4
SLN Growth rating performance
SLN Growth Metrics
Annual
Quarterly
LTM
Industry Median
5Y Historical Average
Benchmark
Competing with SLN Growth
Overview
Ratings
Intrinsic Value
Valuation
Growth
Profitability
Health
Capital allocation
Momentum
Earnings
Dividends
Company name | Market Cap | Growth score | Revenue Growth
(5Y CAGR) | Revenue Growth
(YoY) | Revenue Growth
(FWD) | EPS Growth
(5Y CAGR) | EPS Growth
(YoY) | EPS Growth
(FWD) | FCF Growth
(5Y CAGR) | FCF Growth
(YoY) |
$211.4B | 6.4 | 166.0% | (42.1%) | (18.3%) | (0.7%) | (39.1%) | (64.1%) | 39.5% | 6.6% | |
$402.0B | 7.6 | 18.9% | 25.0% | 19.9% | 6.7% | (17.3%) | 23.5% | 14.5% | 0.0% | |
$125.5B | 6.8 | 21.5% | 11.5% | 6.8% | N/A | N/A | (988.1%) | N/A | N/A | |
$74.0B | 5.5 | 12.6% | 8.3% | 3.4% | 16.1% | 10.3% | 9.5% | 12.5% | (5.7%) | |
$38.1B | 6.2 | 106.9% | 127.3% | 76.7% | (9.7%) | (57.5%) | (141.9%) | N/A | (70.8%) | |
$31.3B | 5.4 | 59.2% | 23.0% | 16.9% | (23.2%) | (38.5%) | (55.3%) | (36.7%) | N/A | |
$27.1B | 6.1 | 83.9% | (54.1%) | (28.2%) | 29.6% | N/A | (182.9%) | N/A | (79.0%) | |
$14.8B | 3.8 | 14.5% | 14.8% | 9.3% | (35.1%) | (91.0%) | 3,612.9% | (18.0%) | (47.6%) | |
$14.6B | 5.7 | (100.0%) | N/A | N/A | (7.1%) | (94.8%) | 6.8% | 44.6% | 84.8% | |
$14.0B | 7.5 | 14.7% | 23.6% | 10.7% | N/A | 25.6% | 9.9% | N/A | 44.5% | |
$1,846.9M | 5.0 | 50.5% | 50.5% | 50.7% | (11.2%) | (16.6%) | (35.6%) | 2.7% | (45.5%) |
FAQ
What is the Silence Therapeutics plc (SLN) revenue growth?
The Silence Therapeutics plc (SLN) revenue growth is (42.1%), which is lower than the industry median of 13.1% and the 5-year historical average of 327.1%.
What is the Silence Therapeutics plc (SLN) operating income growth?
The Silence Therapeutics plc (SLN) operating income growth is 23.4%, compared to the industry median of 0.6% and the 5-year historical average of 20.3%.
What is the Silence Therapeutics plc (SLN) EPS (Earnings Per Share) growth?
The Silence Therapeutics plc (SLN) EPS growth is (39.1%), compared to the industry median of (20.7%) and the 5-year historical average of 6.3%.
What is the Silence Therapeutics plc (SLN) Free Cash Flow (FCF) growth?
The Silence Therapeutics plc (SLN) Free Cash Flow growth is 6.6%, compared to the industry median of (1.5%) and the 5-year historical average of 146.1%.